Today’s edition of the NCI Cancer Bulletin features another natural product clinical trial, this time for depsipeptide in T-cell lymphoma.
Depsipeptide (Romidepsin or FR901228) is an early histone deacetylase inhibitor isolated from fermentation of Chromobacterium violaceum. Several histone deacetylase inhibitors are in clinical trials for various cancers and many are derived from natural products. However, the first HDAC inhibitor approved by FDA is a synthetic compound, SAHA or vorinostat (Zolinza), also for T-cell lymphoma.
What is it about T-cell lymphoma that attracts the development of HDAC inhibitors??? Hmmm.